Literature DB >> 7895769

Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell.

H Mogami1, H Shibata, R Nobusawa, H Ohnota, F Satou, J Miyazaki, I Kojima.   

Abstract

We studied the mechanism of action of KAD-1229, a non-sulfonylurea compound shown to stimulate insulin secretion, in a glucose responsive insulinoma cell line, MIN 6 cells. In microsomal fraction of MIN 6 cells, KAD-1229 displaced binding of [3H]glibenclamide in a concentration-dependent manner. The dissociation constant and the maximum binding capacity were 0.61 nM and 8.70 pmol/mg.protein, respectively. In inside out configuration of patch-clamp technique, KAD-1229 attenuated the opening of ATP-sensitive K+ channels. The effect of KAD-1229 was detected at 10(-8) M, and 10(-5) M KAD-1229 almost completely blocked the activity of ATP-sensitive K+ channel. When membrane potential was monitored by a perforated mode of patch clamp, KAD-1229 induced depolarization of plasma membrane, which was followed by a burst of action potentials. These action potentials were blocked by cobalt. In a fura-2-loaded single MIN 6 cell, KAD evoked an elevation of intracellular free Ca2+ concentration, [Ca2+]i. The KAD-1229-mediated elevation of [Ca2+]i was attenuated by either removal of extracellular Ca2+ or an addition of nifedipine. Finally, KAD-1229 augmented insulin secretion in MIN 6 cells in a concentration-dependent manner. KAD-1229 also enhanced the effect of glucose and nifedipine inhibited the action of KAD-1229 on insulin secretion. These results indicate that KAD-1229 stimulates insulin secretion by stimulating Ca2+ influx and that, despite the lack of sulfonylurea structure, KAD-1229 binds to sulfonylurea receptors and inhibits the activity of ATP-sensitive K+ channel in MIN 6 cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7895769     DOI: 10.1016/0922-4106(94)90036-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator Cl- channels by non-sulphonylurea hypoglycaemic agents.

Authors:  Z Cai; K A Lansdell; D N Sheppard
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

2.  Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel.

Authors:  F Reimann; P Proks; F M Ashcroft
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Structural Insights Into the High Selectivity of the Anti-Diabetic Drug Mitiglinide.

Authors:  Mengmeng Wang; Jing-Xiang Wu; Lei Chen
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

4.  Effect of a non-sulphonylurea hypoglycaemic agent, KAD-1229 on hormone secretion in the isolated perfused pancreas of the rat.

Authors:  M Kinukawa; H Ohnota; Y Ajisawa
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

Review 5.  Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.

Authors:  Lisa Kitasato; Taiki Tojo; Yuko Hatakeyama; Ryo Kameda; Takehiro Hashikata; Minako Yamaoka-Tojo
Journal:  Cardiovasc Diabetol       Date:  2012-06-29       Impact factor: 9.951

6.  Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy.

Authors:  Kohei Kaku; Nobuya Inagaki; Naoki Kobayashi
Journal:  Diabetes Ther       Date:  2014-02-01       Impact factor: 2.945

7.  A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agen.

Authors:  Kenji Sugawara; Kohei Honda; Yoshie Reien; Norihide Yokoi; Chihiro Seki; Harumi Takahashi; Kohtaro Minami; Ichiro Mori; Akio Matsumoto; Haruaki Nakaya; Susumu Seino
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

Review 8.  Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus.

Authors:  Hiroyuki Konya; Tomoyuki Katsuno; Taku Tsunoda; Yuzo Yano; Mai Kamitani; Masayuki Miuchi; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  Diabetes Metab Syndr Obes       Date:  2013-09-02       Impact factor: 3.168

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.